# Depemokimab approval and clinical use in Europe > Live situation record from CLSTR: https://clstr.news/situations/depemokimab-approval-and-clinical-use-in-europe > Updated: 2026-10-05T08:47:00.000Z. Sources: 21. Developments: 2. Medical experts initially highlighted the efficacy of depemokimab, a monoclonal antibody targeting interleukin 5 (IL-5), for treating severe eosinophilic asthma and nasal polyposis. During the European Respiratory Society congress, researchers noted that the drug provides rapid clinical benefits and maintains effectiveness for up to two years, characterized by a unique administration schedule of one dose every six months. Following these clinical presentations, the European Commission approved depemokimab (Exdensur) as the first ultra-long-acting biologic for treating severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps. Clinical data from the SWIFT and ANCHOR phase III trials supported its sustained efficacy. In Ireland, applications have been submitted for potential reimbursement, with medical professionals noting the twice-yearly dosing regimen could improve treatment adherence and reduce the burden of frequent administration. ## Timeline ### 2026-10-05: European Commission approves depemokimab for severe asthma The European Commission has approved depemokimab, an ultra-long-acting biologic for severe asthma and chronic rhinosinusitis, featuring a twice-yearly dosing regimen to improve patient adherence. 3 sources. https://clstr.news/cluster/european-commission-approves-depemokimab-for-severe-asthma ### 2026-09-14: Medical advancements and biotech policy updates in Europe Medical experts report long-term efficacy for depemokimab in treating asthma and nasal polyposis, while European biotech leaders meet in Brussels to discuss the Biotech Act and improving patient access to care. 19 sources. https://clstr.news/cluster/brussels-meeting-addresses-eu-biotech-competitiveness-and-the-biotech-act --- Cite as: Depemokimab approval and clinical use in Europe. CLSTR, https://clstr.news/situations/depemokimab-approval-and-clinical-use-in-europe